SCHEDULE 13G/A: Vivo Entities Amend Stake in Cidara Therapeutics, Disclosing Combined 5.3% Beneficial Ownership

Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity, LLC, Vivo Opportunity Cayman Fund, L.P., and Vivo Opportunity Cayman, LLC have jointly filed an amendment to their Schedule 13G, disclosing a combined beneficial ownership of approximately 5.3% of Cidara Therapeutics, Inc.'s common stock as of March 31, 2025.

Summary

• Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity, LLC, Vivo Opportunity Cayman Fund, L.P., and Vivo Opportunity Cayman, LLC (collectively, "Vivo Entities") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Cidara Therapeutics, Inc.
• As of March 31, 2025, the Vivo Entities collectively beneficially own 684,276 shares of Cidara Therapeutics, Inc. Common Stock.
• This represents approximately 5.3% of the 12,969,823 shares of Common Stock issued and outstanding as of May 5, 2025, as reported by Cidara Therapeutics, Inc. in its Form 10-Q filed on May 8, 2025.
• Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC, beneficially own 612,276 shares, representing 4.7% of the class, with sole voting and dispositive power over these shares.
• Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC, beneficially own 72,000 shares, representing 0.6% of the class, with sole voting and dispositive power over these shares.
• The filing states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: Neutral. This is a routine regulatory filing disclosing beneficial ownership. It does not contain positive or negative news about the company's operations or financial performance, nor does it indicate any intent to influence control.

Positives

• A significant institutional investor group, Vivo Entities, maintains a substantial stake in Cidara Therapeutics, Inc., indicating continued interest.
• The filing provides transparency regarding the beneficial ownership structure of the Vivo Entities in Cidara Therapeutics, Inc.

Negatives

• The document is a routine ownership disclosure and does not contain new positive operational or financial news for Cidara Therapeutics, Inc.

Risks

• The document itself does not detail specific risks related to Cidara Therapeutics, Inc.'s operations or financial health, as it is a beneficial ownership report.
• Investment in Cidara Therapeutics, Inc. is subject to general market risks and risks inherent to the biotechnology sector, though these are not discussed in this specific filing.

Future Outlook

This Schedule 13G/A filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Cidara Therapeutics, Inc.'s future performance or strategic outlook. It only reflects the current ownership stake of the reporting entities.

Management Comments

• Kevin Dai, Managing Member of Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC, certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing is a routine disclosure of institutional ownership in a biotechnology company. Such filings provide transparency on significant shareholder positions but do not typically offer insights into industry trends or competitive dynamics. Cidara Therapeutics, Inc. operates in the biotechnology sector, which is characterized by high R&D costs, regulatory hurdles, and potential for significant breakthroughs.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can be viewed as a vote of confidence, though the filing explicitly states no intent to influence control.

Next Steps

• The reporting persons will continue to file amendments to Schedule 13G if there are material changes to their beneficial ownership percentage (e.g., crossing a 1% threshold up or down, or exceeding 10% ownership).

Key Dates

Keywords

Cidara Therapeutics, Vivo Opportunity Fund, Vivo Opportunity, Schedule 13G/A, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Biotechnology, CDTX